| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Thyrotropin-releasing hormone receptor, TRH-R, Thyroliberin receptor, TRHR |
| Entrez GeneID | 7201 |
| WB Predicted band size | 45.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This TRHR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 209-238 amino acids from the Central region of human TRHR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL20RA抗体的示例参考文献(注：以下为假设性示例，实际文献需通过数据库验证)：
1. **文献名称**: "Therapeutic targeting of IL-20RA signaling in psoriasis with a monoclonal antibody"
**作者**: Miller, R., et al.
**摘要**: 研究开发了一种靶向IL20RA的单克隆抗体，在银屑病小鼠模型中验证其疗效。结果显示抗体显著抑制角质形成细胞过度增殖及促炎因子(如IL-17、TNF-α)，提示其作为银屑病治疗的潜在策略。
2. **文献名称**: "IL-20RA blockade ameliorates inflammation in experimental autoimmune encephalomyelitis"
**作者**: Chen, L., et al.
**摘要**: 通过抗IL20RA抗体干预实验性自身免疫性脑脊髓炎(EAE)模型，发现其可减少中枢神经系统炎症浸润及Th17细胞分化，表明IL20RA信号在多发性硬化等神经炎症疾病中的关键作用。
3. **文献名称**: "Neutralizing IL-20RA antibody suppresses osteoclastogenesis in rheumatoid arthritis"
**作者**: Tanaka, K., et al.
**摘要**: 研究报道了一种中和抗体，通过阻断IL20RA信号通路抑制破骨细胞分化，并在类风湿性关节炎患者滑膜细胞中验证其抗炎及骨保护作用，为联合治疗提供新思路。
4. **文献名称**: "Anti-IL20RA antibody as a novel biomarker in inflammatory bowel disease"
**作者**: Wang, Q., et al.
**摘要**: 探索IL20RA抗体在炎症性肠病(IBD)患者血清中的表达水平，发现其与疾病活动度正相关，并证实抗体阻断可减轻结肠黏膜损伤及肠道炎症反应。
**注意**：以上文献为示例性质，实际引用时需通过PubMed、Google Scholar等平台检索真实文献，使用关键词如“IL20RA antibody therapeutic”、“IL-20 receptor alpha blockade”等，并筛选近5年研究以获取最新进展。
The IL-20RA (Interleukin-20 Receptor Alpha) antibody is a research tool targeting the IL-20RA subunit, a key component of the interleukin-20 receptor complex. IL-20RA belongs to the IL-10 receptor family and pairs with IL-20RB to form a functional heterodimeric receptor for IL-19. IL-20. and IL-24. These cytokines are involved in inflammatory and immune responses, influencing processes like keratinocyte proliferation, angiogenesis, and tissue remodeling. Dysregulation of IL-20RA signaling is linked to autoimmune disorders (e.g., psoriasis, rheumatoid arthritis) and cancers due to its role in promoting cell survival and inflammation.
IL-20RA antibodies are primarily used to study receptor expression, signaling mechanisms, and cytokine-receptor interactions in vitro and in vivo. They enable detection of IL-20RA protein levels via techniques such as Western blot, immunohistochemistry, and flow cytometry. Additionally, neutralizing IL-20RA antibodies are explored for therapeutic potential, aiming to block pathogenic signaling in diseases like psoriasis or inflammatory skin conditions. Monoclonal antibodies against IL-20RA have shown promise in preclinical models, highlighting their relevance in drug development. Research using these antibodies contributes to understanding the IL-20 axis in immune dysregulation and tissue homeostasis, bridging molecular insights to clinical applications.
×
